154 related articles for article (PubMed ID: 28333014)
1. Single Nucleotide Polymorphism TGFβ1 R25P Correlates with Acute Toxicity during Neoadjuvant Chemoradiotherapy in Rectal Cancer Patients.
Smith JJ; Wasserman I; Milgrom SA; Chow OS; Chen CT; Patil S; Goodman KA; Garcia-Aguilar J
Int J Radiat Oncol Biol Phys; 2017 Apr; 97(5):924-930. PubMed ID: 28333014
[TBL] [Abstract][Full Text] [Related]
2. Acute toxicity of radiochemotherapy in rectal cancer patients: a risk particularly for carriers of the TGFB1 Pro25 variant.
Schirmer MA; Mergler CP; Rave-Fränk M; Herrmann MK; Hennies S; Gaedcke J; Conradi LC; Jo P; Beissbarth T; Hess CF; Becker H; Ghadimi M; Brockmöller J; Christiansen H; Wolff HA
Int J Radiat Oncol Biol Phys; 2012 May; 83(1):149-57. PubMed ID: 22000747
[TBL] [Abstract][Full Text] [Related]
3. [Impact of CCND1 A870G polymorphism on acute adverse events in postoperative rectal cancer patients treated with adjuvant concurrent chemoradiotherapy].
Qiao Y; Ren H; Huang Y; DU ZL; Yu DK; Jin J; Li YX; Lin DX; Tan W
Zhonghua Zhong Liu Za Zhi; 2013 Apr; 35(4):268-72. PubMed ID: 23985254
[TBL] [Abstract][Full Text] [Related]
4. Induction Chemotherapy Reduces Patient-reported Toxicities During Neoadjuvant Chemoradiation with Intensity Modulated Radiotherapy for Rectal Cancer.
Ng SY; Colborn KL; Cambridge L; Cercek A; Reidy-Lagunes DL; Segal N; Stadler Z; Saltz LB; Paty PB; Guillem J; Weiser MR; Nash G; Garcia-Aguilar J; Goodman KA
Clin Colorectal Cancer; 2019 Sep; 18(3):167-174. PubMed ID: 31104990
[TBL] [Abstract][Full Text] [Related]
5. Potential Role of Single Nucleotide Polymorphisms of XRCC1, XRCC3, and RAD51 in Predicting Acute Toxicity in Rectal Cancer Patients Treated With Preoperative Radiochemotherapy.
Osti MF; Nicosia L; Agolli L; Gentile G; Falco T; Bracci S; Di Nardo F; Minniti G; De Sanctis V; Valeriani M; Maglio M; Borro M; Simmaco M; Enrici RM
Am J Clin Oncol; 2017 Dec; 40(6):535-542. PubMed ID: 25811296
[TBL] [Abstract][Full Text] [Related]
6. Common variants of GSTP1, GSTA1, and TGFβ1 are associated with the risk of radiation-induced fibrosis in breast cancer patients.
Terrazzino S; La Mattina P; Gambaro G; Masini L; Franco P; Canonico PL; Genazzani AA; Krengli M
Int J Radiat Oncol Biol Phys; 2012 Jun; 83(2):504-11. PubMed ID: 22079734
[TBL] [Abstract][Full Text] [Related]
7. Small bowel dose parameters predicting grade ≥ 3 acute toxicity in rectal cancer patients treated with neoadjuvant chemoradiation: an independent validation study comparing peritoneal space versus small bowel loop contouring techniques.
Banerjee R; Chakraborty S; Nygren I; Sinha R
Int J Radiat Oncol Biol Phys; 2013 Apr; 85(5):1225-31. PubMed ID: 23182394
[TBL] [Abstract][Full Text] [Related]
8. Intensity modulated radiation therapy reduces gastrointestinal toxicity in locally advanced pancreas cancer.
Prasad S; Cambridge L; Huguet F; Chou JF; Zhang Z; Wu AJ; O'Reilly EM; Allen PJ; Goodman KA
Pract Radiat Oncol; 2016; 6(2):78-85. PubMed ID: 26577010
[TBL] [Abstract][Full Text] [Related]
9. Pharmacogenetic study in rectal cancer patients treated with preoperative chemoradiotherapy: polymorphisms in thymidylate synthase, epidermal growth factor receptor, GSTP1, and DNA repair genes.
Páez D; Salazar J; Paré L; Pertriz L; Targarona E; del Rio E; Barnadas A; Marcuello E; Baiget M
Int J Radiat Oncol Biol Phys; 2011 Dec; 81(5):1319-27. PubMed ID: 21570215
[TBL] [Abstract][Full Text] [Related]
10. Is the irradiated small bowel volume still a predictor for acute lower gastrointestinal toxicity during preoperative concurrent chemo-radiotherapy for rectal cancer when using intensity-modulated radiation therapy?
Xu B; Guo Y; Chen Y; Lu H; Tang T; Yue Z; Guan G; Chi P; Lin C
Radiat Oncol; 2015 Dec; 10():257. PubMed ID: 26684643
[TBL] [Abstract][Full Text] [Related]
11. Outcomes in locally advanced rectal cancer with highly selective preoperative chemoradiotherapy.
Williamson JS; Jones HG; Davies M; Evans MD; Hatcher O; Beynon J; Harris DA;
Br J Surg; 2014 Sep; 101(10):1290-8. PubMed ID: 24924947
[TBL] [Abstract][Full Text] [Related]
12. Prognosis factors for recurrence in patients with locally advanced rectal cancer preoperatively treated with chemoradiotherapy and adjuvant chemotherapy.
Arredondo J; Baixauli J; Beorlegui C; Arbea L; Rodríguez J; Sola JJ; Chopitea A; Hernández-Lizoáin JL
Dis Colon Rectum; 2013 Apr; 56(4):416-21. PubMed ID: 23478608
[TBL] [Abstract][Full Text] [Related]
13. A study of ethnic differences in TGFβ1 gene polymorphisms and effects on the risk of radiation pneumonitis in non-small-cell lung cancer.
Niu X; Li H; Chen Z; Liu Y; Kan M; Zhou D; Li Z; Ye X; Shen S; Lv C; Lu S
J Thorac Oncol; 2012 Nov; 7(11):1668-75. PubMed ID: 23059779
[TBL] [Abstract][Full Text] [Related]
14. Organ preservation for clinical T2N0 distal rectal cancer using neoadjuvant chemoradiotherapy and local excision (ACOSOG Z6041): results of an open-label, single-arm, multi-institutional, phase 2 trial.
Garcia-Aguilar J; Renfro LA; Chow OS; Shi Q; Carrero XW; Lynn PB; Thomas CR; Chan E; Cataldo PA; Marcet JE; Medich DS; Johnson CS; Oommen SC; Wolff BG; Pigazzi A; McNevin SM; Pons RK; Bleday R
Lancet Oncol; 2015 Nov; 16(15):1537-1546. PubMed ID: 26474521
[TBL] [Abstract][Full Text] [Related]
15. Bowel Dysfunction After Low Anterior Resection With Neoadjuvant Chemoradiotherapy or Chemotherapy Alone for Rectal Cancer: A Cross-Sectional Study from China.
Qin Q; Huang B; Cao W; Zhou J; Ma T; Zhou Z; Wang J; Wang L
Dis Colon Rectum; 2017 Jul; 60(7):697-705. PubMed ID: 28594719
[TBL] [Abstract][Full Text] [Related]
16. Efficacy and safety of neoadjuvant intensity-modulated radiotherapy with concurrent capecitabine for locally advanced rectal cancer.
Wang L; Li ZY; Li ZW; Li YH; Sun YS; Ji JF; Gu J; Cai Y
Dis Colon Rectum; 2015 Feb; 58(2):186-92. PubMed ID: 25585076
[TBL] [Abstract][Full Text] [Related]
17. Acute small-bowel toxicity during neoadjuvant combined radiochemotherapy in locally advanced rectal cancer: determination of optimal dose-volume cut-off value predicting grade 2-3 diarrhoea.
Reis T; Khazzaka E; Welzel G; Wenz F; Hofheinz RD; Mai S
Radiat Oncol; 2015 Jan; 10():30. PubMed ID: 25636703
[TBL] [Abstract][Full Text] [Related]
18. Low Toxicity in Inflammatory Bowel Disease Patients Treated With Abdominal and Pelvic Radiation Therapy.
White EC; Murphy JD; Chang DT; Koong AC
Am J Clin Oncol; 2015 Dec; 38(6):564-9. PubMed ID: 24401668
[TBL] [Abstract][Full Text] [Related]
19. Intensified neoadjuvant chemoradiotherapy in locally advanced rectal cancer -- impact on long-term quality of life.
Kripp M; Wieneke J; Kienle P; Welzel G; Brade J; Horisberger K; Wenz F; Post S; Gencer D; Hofmann WK; Hofheinz RD
Eur J Surg Oncol; 2012 Jun; 38(6):472-7. PubMed ID: 22349986
[TBL] [Abstract][Full Text] [Related]
20. Pharmacogenetic Analysis of INT 0144 Trial: Association of Polymorphisms with Survival and Toxicity in Rectal Cancer Patients Treated with 5-FU and Radiation.
Bohanes P; Rankin CJ; Blanke CD; Winder T; Ulrich CM; Smalley SR; Rich TA; Martensen JA; Benson AB; Mayer RJ; Cripps CM; Danenberg K; Makar KW; Zhang W; Benedetti JK; Lenz HJ
Clin Cancer Res; 2015 Apr; 21(7):1583-90. PubMed ID: 25589620
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
